Company Filing History:
2 out of 1,311 
1 out of 420 
1 out of 820 
Years Active: 2013-2021
Title: Shiroh Futaki: Innovator in Peptide and Lipid Membrane Technologies
Introduction
Shiroh Futaki is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of peptides and lipid membrane structures for cellular delivery systems. With a total of 4 patents, his work has the potential to advance therapeutic techniques in immunology and gene delivery.
Latest Patents
Futaki's latest patents include innovative technologies such as a peptide designed for cytosolic delivery. This peptide is represented by a specific formula that enhances the efficiency of delivering therapeutic agents into cells. Another notable patent is a lipid membrane structure that possesses intranuclear migrating properties. This structure is engineered to deliver substances directly into the nucleus of a cell, particularly targeting immunocytes like dendritic cells. The lipid membrane is modified with polypeptides that promote its migration into the nucleus, thereby facilitating the effective delivery of nucleic acids.
Career Highlights
Throughout his career, Shiroh Futaki has worked with esteemed institutions such as the Japan Science and Technology Agency and Hokkaido University. His research has focused on the intersection of chemistry and biology, leading to breakthroughs in drug delivery systems. His innovative approaches have garnered attention in the scientific community, contributing to advancements in medical research.
Collaborations
Futaki has collaborated with notable colleagues, including Hideyoshi Harashima and Kentaro Kogure. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Shiroh Futaki's contributions to peptide and lipid membrane technologies exemplify the innovative spirit of modern science. His patents and collaborative efforts continue to pave the way for advancements in therapeutic delivery systems.